Imagine being diagnosed with a serious illness and then discovering that the medicine keeping you alive costs more than your entire monthly income. This was the reality for Sarojam Radhakrishnan, a breast cancer patient from Kerala, whose monthly treatment with the drug Ribociclib reportedly cost around ₹63,480. Rather than accept that as the end of the conversation, she approached the Kerala High Court seeking relief — not just for herself, but for other patients facing the same impossible choice. Her case raises a question far bigger than one prescription: does the right to affordable healthcare actually mean something in Indian law, or does it stop where a patient's ability to pay runs out?
What Did the Kerala High Court Look At?
In 2022, Sarojam approached the Kerala High Court seeking affordable access to her cancer medication, asking the Court to consider mechanisms available under India's intellectual property and public health framework that could make the drug available at a significantly lower cost. The Court examined the broader public interest involved and looked into whether affordable alternatives could realistically be considered. Its observations pointed to a principle that matters well beyond this one case: a life-saving medicine existing on paper isn't the same as it being genuinely accessible to the patients who need it.
Does the Constitution Actually Protect a "Right to Health"?
Indian courts have repeatedly interpreted Article 21 of the Constitution — the right to life — to include the right to live with dignity, and that has been extended to cover access to essential healthcare. The logic is straightforward: a right to life that doesn't account for whether a person can actually access treatment they need to stay alive is an incomplete promise. This doesn't mean the government or courts can simply order any medicine to be made free — but it does mean that affordability and access are treated as constitutional concerns, not just market outcomes, when life-saving treatment is involved.
Why Does This Case Matter Beyond One Patient?
This dispute sits at the intersection of a few different legal and policy tensions that affect far more than one prescription:
Patents versus access. Drug patents exist to reward the enormous cost of developing new medicines, but when a patented drug is priced out of reach for most patients, the law has to grapple with how to balance rewarding innovation against ensuring the medicine actually reaches people.
India's role as an affordable-medicine supplier. India has long been known globally for producing affordable generic medicines, which makes cases like this especially significant for how future drug-pricing and patent disputes get resolved.
Impact on families, not just patients. Cancer and other high-cost treatments routinely push families into serious financial strain — the legal question of affordability is really a question about whether treatment forces a choice between survival and financial ruin.
What Legal Tools Exist for Drug Affordability?
A few mechanisms under Indian law are specifically designed to address situations where patented medicines are priced out of reach:
Compulsory licensing under the Patents Act, 1970 allows the government, in specific circumstances, to permit a generic manufacturer to produce a patented drug without the patent holder's consent, usually with royalty paid to the patent holder — used when a patented invention isn't reasonably accessible or affordable to the public.
Price control mechanisms under the National Pharmaceutical Pricing Authority can cap prices for certain essential medicines.
Public interest litigation and writ petitions, like the one in this case, allow patients and advocacy groups to bring affordability concerns directly before constitutional courts.
None of these tools guarantee a specific outcome in any individual case — they exist as avenues, and how they apply depends heavily on the specific drug, patent status, and facts involved.
What This Means for Patients Facing Similar Costs
If you or a family member is facing an unaffordable treatment cost, a few practical points matter. First, check whether a generic or biosimilar version of the medicine exists or is likely to become available — many patented drugs eventually have compulsory-licensed or off-patent alternatives. Second, look into patient assistance programs, which several pharmaceutical companies run for exactly this situation. Third, if the cost is genuinely unaffordable and no alternative exists, consulting a lawyer about the legal avenues above — including whether a public interest angle applies — is worth exploring, though outcomes are never guaranteed and depend on the specific circumstances.
What to Do Next
Ask your treating hospital or oncologist about generic or biosimilar alternatives before assuming a specific branded drug is the only option.
Check for patient assistance programs run by the manufacturer or by nonprofit health organizations, which sometimes subsidies high-cost treatments significantly.
Review your health insurance policy closely for coverage gaps, and if a genuine claim is rejected, escalate it through the insurer's grievance process and, if needed, the insurance ombudsman.
Document your treatment costs and correspondence thoroughly if you're considering any legal or advocacy route.
Consult a lawyer familiar with health and patent law if the cost genuinely threatens your ability to continue treatment — this is a specialized area, and general awareness is a starting point, not a substitute for advice on your specific situation.
Disclaimer
This article is general legal information for educational purposes and does not constitute legal advice, and does not guarantee any outcome in ongoing or future legal proceedings. Please consult a qualified lawyer or patient advocacy organization for guidance specific to your situation.